Noteworthy Shaman inverts its drug development model

With its long-term capital security in mind, Shaman Pharmaceuticals Inc. has decided to focus on the pharmaceutical industry as its primary customer and will concentrate its development efforts in diseases best modeled by whole animal testing.

Although the South San Francisco company last week said it will continue to use an ethnobotany approach to discover new compounds, its new priorities are intended to further differentiate its programs from drug discovery technologies pursued by other biotechnology companies.